Alector Inc.
Clinical trials sponsored by Alector Inc., explained in plain language.
A clinical-stage biotechnology company developing therapies for neurodegenerative diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New drug targets genetic dementia in small trial
Disease control CompletedThis study tested a drug called AL001 in 33 people who carry a gene mutation that causes frontotemporal dementia, a brain disease that affects personality and language. The goal was to see if the drug is safe and how it affects certain proteins in the body. The trial was open-lab…
Phase 2 • Sponsor: Alector Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Could this injection help slow Alzheimer's?
Disease control CompletedThis study tested an experimental drug called AL002 in 356 people with early Alzheimer's disease. The goal was to see if it could slow down memory and thinking problems compared to a placebo. Participants received either the drug or a dummy injection, and their symptoms were trac…
Phase 2 • Sponsor: Alector Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC